Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capio in conjunction with its acquisition of PR Vård
Mandate

Vinge advises Capio in conjunction with its acquisition of PR Vård

March 31, 2022 Employment and Benefits IT, Telecommunications and Outsourcing EU, Competition and Regulatory M&A Public Procurement

Vinge is advising Capio in connection with its acquisition of all shares in PR Vård Hemsjukvåd AB and PR Vård Mottagning AB.

PR Vård conducts home healthcare operations in five out of eight primary health areas in Stockholm as well as one surgery for children and young people and one healthcare surgery in Södermalm. PR Vård has 600 employees and performs approximately 1 million home healthcare visits per year. The acquisition is subject to approval by the Swedish Competition Authority.

Vinge’s team consisted of partner Anders Strid and Jenny Sandlund (project manager), Victoria Gunnerek (public procurement), Adam Löwenstein (tenancy law), Alexander Lindeberg (IT/GDPR), Anna Ståhlklo (employment law), Fredrik Löwenklou (M&A) as well as Anna Palmérus (competition law).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025